Abstract 1053P
Background
ICIs used across multiple disease sites including both early and advanced stage cancers. Systemic inflammatory markers including neutrophil to lymphocyte ratios (NLR), platelet to lymphocyte ratios (PLR) and lymphocyte to monocyte ratios (LMR) has been found to be prognostic across different tumor types, but less is known about their prognostic role in patients receiving ICIs. Here we used population-level administrative data to evaluate the potential association between NLR, PLR and LMR and overall survival (OS) among patients receiving ICIs.
Methods
We used administrative data deterministically linked across databases to identify a cohort of patients with solid tumors initiating ICI therapy in Ontario, Canada from June 2012 to October 2018 and obtained information on baseline demographics, clinical covariates, inflammatory markers (NLR, PLR, LMR) at the start of ICI, and overall survival (OS). We applied multivariable Cox proportional hazard models to evaluate the impact of NLR, PLR, and LMR on OS, adjusting for sex, age, cancer center, autoimmune history, recent hospitalization and comorbidity score.
Results
Among 4683 patients, median age was 67, 57% male; 46% had lung cancer, 35% melanoma, 9% renal cancers; 40% received nivolumab, 36% pembrolizumab, 17% ipilimumab. Median OS was 317 days. Using previous cutoffs in the literature, 44% of patients had a high NLR (≥ 5), 58% high PLR (≥ 200), and 60% high LMR (≥ 1.5). Among all patients, those with high NLR (aHR=1.80, 95% CI [1.65-1.97] p
Conclusions
Among cancer patients receiving ICIs, higher NLR and PLR and lower LMR were prognostic of OS across cancer types. Further studies validating their prognostic role in ICI therapy is warranted.
Legal entity responsible for the study
The authors.
Funding
ASCO / Conquer Cancer Foundation - Young Investigator Award.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
927P - Preliminary results of the BROADEN study: Burden of human papillomavirus-related head and neck cancers
Presenter: Laia Alemany
Session: Poster session 03
928P - Radiomic analysis based on machine learning of multi-MR sequences to assess early treatment response in locally advanced nasopharyngeal carcinoma
Presenter: Lei Qiu
Session: Poster session 03
929P - Advanced laryngeal squamous cell carcinoma prognosis and machine learning insights
Presenter: Tala Alshwayyat
Session: Poster session 03
Resources:
Abstract
930P - Real-world data analysis of oncological outcomes in patients with pathological extranodal extension (ENE) in OSCC: A proposal to refine the pathological nodal staging system
Presenter: Abhinav Thaduri
Session: Poster session 03
931P - Deep learning models for predicting short-term efficacy in locally advanced nasopharyngeal carcinoma
Presenter: Kexin Shi
Session: Poster session 03
932P - Accuracy and prognostic implications of extranodal extension on radiologic imaging in HPV-positive oropharyngeal cancer (HNCIG-ENE): A multinational, real-world study
Presenter: Hisham Mehanna
Session: Poster session 03
933P - Prediction of survival in patients with head and neck merkel cell carcinoma: Statistical and machine-learning approaches
Presenter: Jehad Yasin
Session: Poster session 03
934P - Harnessing artificial intelligence on real-world data to predict recurrence in head and neck squamous cell carcinoma patients: The HNC-TACTIC study
Presenter: Hisham Mehanna
Session: Poster session 03
936P - Chronic pain in cancer survivors: Head and neck versus other cancers
Presenter: Rong Jiang
Session: Poster session 03